Dupilumab for Adult and Adolescent Patients With Primary Eosinophilic Colitis.

INTRODUCTION

Eosinophilic colitis (EoC) currently has limited options to induce histologic and clinical remission. Dupilumab is a human monoclonal antibody against the interleukin-4 receptor ɑ subunit effective in eosinophilic esophagitis (EoE) and other non-EoE eosinophilic gastrointestinal disorders.

METHODS

We conducted a retrospective chart review to assess the histoclinical response of patients with EoC treated with dupilumab.

RESULTS

Of 4 included patients, all 4 improved histologically, with 3 patients attaining histologic remission. All patients' symptom scores significantly improved, and 1 patient was asymptomatic on dupilumab.

DISCUSSION: This retrospective case series provides preliminary evidence that dupilumab may be an effective treatment option for EoC.